Imperial College London spin-out Circassia completes Phase II trials into grass allergy treatment.
Circassia, a life sciences spin-out of Imperial College London, has completed Phase II trials into its hay fever treatment.
The UK-based company found that its grass allergy treatment for hay fever sufferers delivered significantly improved allergy symptoms over the pollen period, compared to a control group on placebos.
The life sciences firm, which also developing treatments for immune responses to cats and dust mites, has raised £105m ($178m) since founding in 1998. Among its backers are Imperial College London’s tech…
